FDA Approves Papzimeos, a New Treatment for Adults with Recurrent Respiratory Papillomatosis
The FDA has approved Papzimeos, a groundbreaking immunotherapy for adults with recurrent respiratory papillomatosis, offering a new targeted treatment to reduce surgical interventions.
The U.S. Food and Drug Administration (FDA) has granted approval to Papzimeos (zopapogene imadenovec-drba), marking a significant advancement in the treatment of adults suffering from recurrent respiratory papillomatosis (RRP). RRP is a chronic condition characterized by the growth of benign tumors in the respiratory tract, often requiring repeated surgeries to manage the symptoms and prevent airway obstruction.
Papzimeos is a novel immunotherapy that utilizes an adenoviral vector to deliver a fusion antigen derived from HPV types 6 and 11 proteins, the primary viral strains responsible for RRP. Unlike traditional methods that rely heavily on surgical removal of papillomas, this therapy aims to target the underlying cause of the disease. Administered through four subcutaneous injections spaced over a 12-week period, Papzimeos offers a potential long-lasting solution for affected individuals.
The FDA's decision was based on clinical trial results involving 35 patients, where half of them (18 patients) achieved complete eradication of papillomas, eliminating the need for further surgeries during the subsequent 12 months. Impressively, 15 of these patients maintained their response at 24 months post-treatment. Importantly, the therapy demonstrated a favorable safety profile, with no dose-limiting toxicities or adverse events exceeding grade 2.
Helen Sabzevari, Ph.D., President and CEO of Precigen, the company behind Papzimeos, expressed optimism about the approval. She highlighted that this milestone could transform the management of RRP, a condition that has historically relied on frequent surgical interventions. The approval allows broad access to the first therapy specifically targeting the root cause of RRP in adults.
For more detailed information, visit the related press release at Precigen's official site.
Source: https://medicalxpress.com/news/2025-08-fda-papzimeos-adults-recurrent-respiratory.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Uncovering the Hidden Healing Powers of Fibroblasts in Brain Injury Recovery
New research reveals that fibroblasts, cells found in the meninges, play a crucial role in brain injury healing by forming protective scars and coordinating immune responses, opening new avenues for treatment.
Innovative Method Fast-Tracks Measurement of Cell Density to Assess Health and Developmental States
MIT researchers have developed a fast, large-scale method to measure cell density, revealing important insights into cell health, immune activation, and drug responses. This breakthrough enhances our understanding of cellular states and could revolutionize biomedical research.
Herbal Mouthwash Promises Targeted Oral Microbe Management While Supporting Beneficial Bacteria
A new herbal mouthwash developed by Rutgers University selectively targets harmful oral bacteria while preserving beneficial microbes, offering a promising shift in oral health management.
Innovative Biomaterial Demonstrates Potential to Reverse Heart Aging
A new hybrid biomaterial developed by researchers shows promise in reversing age-related changes in heart tissue by targeting the extracellular matrix, opening new possibilities for regenerative therapies.